Kidney Injury by Cisplatin and Renoprotective Strategies.

顺铂引起的肾损伤和肾脏保护策略。

基本信息

批准号：
10579273
负责人：
Zheng Dong
金额：
$ 41.84万
依托单位：
AUGUSTA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-30 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10579273
关键词：
Acute Acute Renal Failure with Renal Papillary Necrosis Animal Model Animals Antineoplastic Agents Autophagocytosis Autophagosome Cancer Patient Cell physiology Cells Chronic Chronic Kidney Failure Cisplatin Conditioned Culture Media Cytoplasm Development Dose Fibroblasts Fibrosis Goals Injury Injury to Kidney Kidney Knockout Mice Long-Term Effects Longitudinal Studies Modeling Mus Normal tissue morphology Organ Pathogenesis Pathology Pharmaceutical Preparations Phenotype Positioning Attribute Production Profibrotic signal Regulation Renal tubule structure Reporting Research Role TP53 gene Testing Tubular formation Work cancer therapy chemotherapy fibrogenesis hypoxia inducible factor 1 inhibition of autophagy inhibitor insight interstitial kidney fibrosis knockout gene long-term sequelae mouse model nephrotoxicity new therapeutic target novel strategies pharmacologic prevent side effect tool tumor

项目摘要

Project Summary The goal of this project is to investigate the long-term sequelae of cisplatin chemotherapy in kidneys. Cisplatin is one of the most widely used and most potent cancer therapy drugs. However, cisplatin chemotherapy is frequently associated with adverse side-effects in kidneys, resulting in acute kidney injury and chronic kidney problems. While the past work has focused on acute kidney injury by cisplatin, very little is known about the chronic or long-term effect of cisplatin treatment in kidneys. A major hurdle in studying the long-term effect of cisplatin is the lack of appropriate animal models. But we and others have recently established the mouse model of repeated low dose cisplatin treatment that leads to renal fibrosis and chronic kidney disease, opening the door to the research of the long-term sequelae of cisplatin chemotherapy in kidneys. Using this model, the current application will investigate autophagy in renal fibrosis and chronic kidney disease following cisplatin treatment. The application is supported by critical preliminary findings: (1) Following cisplatin treatment, autophagy is induced along with the development of chronic kidney pathologies including renal fibrosis; (2) Autophagy inhibitors given after cisplatin treatment can prevent the development of chronic kidney problems; (3) Renal tubular cells may produce and secret specific profibrotic factors in an autophagy-dependent manner; and (4) At the upstream, cisplatin treatment leads to the activation of p53 and hypoxia-inducible factor-1 (HIF-1), two potential regulators of autophagy. Based on these findings, we hypothesize that: Cisplatin treatment leads to the activation of p53 and HIF-1, which induce persistent autophagy in renal tubular cells. Persistent autophagy then triggers a secretory phenotype in these tubular cells for the production and secretion of profibrotic factors, which activate interstitial fibroblasts to promote renal fibrosis and the progression to CKD. We will test this hypothesis by three Specific Aims: (1) test the hypothesis that blockade of autophagy may ameliorate renal fibrosis and CKD following cisplatin treatment, while enhancing chemotherapy in tumors; (2) test the hypothesis that p53 and/or HIF-1 contribute to autophagy activation, renal fibrosis and CKD following cisplatin treatment; and (3) test the hypothesis that renal tubular cells produce profibrotic factors in an autophagy-dependent manner for fibroblast activation and fibrogenesis. Completion of the research will gain significant new insights into the long- term side-effects of cisplatin treatment in kidneys. Moreover, by targeting autophagy and HIF-1, the work may identify novel strategies that not only protect kidneys in cisplatin treatment but also enhance chemotherapy in tumors.

项目摘要该项目的目的是研究肾脏中顺铂化学疗法的长期后遗症。顺铂是最常用，最有效的癌症治疗药物之一。但是，顺铂化学疗法经常与肾脏不良副作用有关，导致急性肾脏受伤和慢性肾脏问题。虽然过去的工作集中于顺铂急性肾脏损伤，但对于肾脏中顺铂治疗的慢性或长期作用知之甚少。一个重大障碍在研究顺铂的长期作用时，缺乏适当的动物模型。但是我们和其他人最近已经建立了重复低剂量顺铂治疗的小鼠模型，该模型导致肾脏纤维化和慢性肾脏疾病，为长期后遗症的研究打开了大门肾脏中的顺铂化疗。使用此模型，当前的应用程序将研究自噬在顺铂治疗后，在肾纤维化和慢性肾脏疾病中。支持该申请通过关键的初步发现：（1）顺铂治疗后，自噬与慢性肾脏病理的发展，包括肾纤维化；（2）给出的自噬抑制剂顺铂治疗可以防止慢性肾脏问题的发展；（3）肾小管细胞可以以自噬依赖性方式产生和秘密的特定特定纤维化因子；（4）在上游，顺铂治疗导致p53和缺氧诱导因子1（HIF-1）的激活，两个自噬的潜在调节剂。基于这些发现，我们假设：顺铂治疗导致p53和HIF-1的激活，它们在肾小管细胞中诱导持续的自噬。然后纤维化因子的分泌，该因子激活间质成纤维细胞以促进肾纤维化和进展到CKD。我们将通过三个特定目的检验这一假设：（1）检验以下假设。封锁自噬可能会在顺铂治疗后改善肾纤维化和CKD，而增强肿瘤的化学疗法；（2）检验p53和/或HIF-1有助于的假设顺铂治疗后，自噬激活，肾纤维化和CKD；（3）检验假设肾小管细胞以自噬依赖性方式产生纤维细胞的纤维化因子激活和纤维发生。研究的完成将获得对长期的重大新见解肾脏中顺铂治疗的术语副作用。而且，通过靶向自噬和HIF-1，工作可能会确定新的策略，这些策略不仅可以保护顺铂治疗中的肾脏，还可以增强肿瘤的化学疗法。